OCGN
Ocugen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.06
+2.91%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.03
From 52W high−57.26%
Volume14.74M
Market cap$359.46M
P/E (TTM)—
P/S (TTM)78.5x
Div yield—
Key dataSep 18, 2026
Open
$1.03
From 52W high
−57.26%
Volume
14.74M
Market cap
$359.46M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.0x
P/E (TTM)
—
RSI (14)
32.7
MomentumView details →
1D Return
+2.91%
YTD Return
−24.07%
SummaryUpdated Jun 1, 2026
Ocugen, Inc. (NASDAQ:OCGN) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Malvern, Pennsylvania. The company went public in December 2014 and has evolved from its initial focus on COVID-19 vaccines to become a specialized developer of gene therapies for inherited retinal diseases. Ocugen is currently advancing multiple clinical programs targeting various forms of blindness, with three potential biologics license applications planned for filing within the next three years.
Similar companies
Latest newsMore news →
SCYNEXIS Inc. appointed Sanjay Subramanian as Chief Financial Officer effective September 9, 2026.10d agoOcugen Inc. dosed the first patient in a global Phase 3 trial (ArMaDa3) of its gene therapy OCU410 for geographic atrophy, initiating pivotal testing.14d agoOcugen dosed the first patient in the global Phase 3 registrational trial of its OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration.19d ago